Takeda Pharmaceutical Company Limited, a global pharmaceutical company, and Jupiter, FL-based Envoy Therapeutics Inc., a recently formed drug discovery company, today announced that they have formed a three-year research alliance aimed at discovering drugs for schizophrenia that will have greater efficacy and safety compared to current therapies.
Developed at Rockefeller University, with its roots in the government funded Gene Expression Nervous System ATlas (GENSAT) project, Envoy’s “bacTRAP” technology combines innovative genetic engineering with new molecular biology techniques for labeling and extracting the protein-making components of specific types of cells.

Leave a Reply

Your email address will not be published. Required fields are marked *